1 November 2008 in Journal of the American Society of Nephrology
MicroRNAs (miRNAs) regulate gene expression by binding the 3′ untranslated region of mRNAs. To define their role in glomerular function, miRNA biogenesis was disrupted in mouse podocytes using a conditional Dicer allele. Mutant mice developed proteinuria by 3 wk after birth and progressed rapidly to end-stage kidney disease. Podocyte pathology included effacement, vacuolization, and hypertrophy with crescent formation. Despite normal expression of WT1, podocytes underwent dedifferentiation, exemplified by cytoskeletal disruption with early transcriptional downregulation of synaptopodin. These abnormalities differed from Cd2ap−/− mice, indicating they were not a general consequence of glomerular disease. Glomerular labeling of ezrin, moesin, and gelsolin was altered at 3 wk, but expression of nestin and α-actinin was unchanged. Abnormal cell proliferation or apoptosis was not responsible for the glomerular injury. Mutant podocytes were incapable of synthesizing mature miRNA, as revealed by their loss of miR-30a. In contrast, expression of glomerular endothelial and mesangial cell miRNAs (miR-126 and miR-145, respectively) was unchanged. These findings demonstrate a critical role for miRNA in glomerular function and suggest a pathway that may participate in the pathogenesis of kidney diseases of podocyte origin. The unique architecture of podocytes may make them especially susceptible to cytoskeletal alterations initiated by aberrant miRNA dynamics.
1 February 2001 in Nature Genetics
1 July 2007 in The American Journal of Pathology
1 June 2013 in Kidney International
1 July 2009 in Current Opinion in Nephrology and Hypertension
MicroRNAs (miRNAs) are regulatory RNAs that act as posttranscriptional repressors by binding the 3' untranslated region of target genes. They have been implicated in diverse biologic and pathologic processes and are emerging as important players in kidney health and disease. Here, we review the latest literature in this exciting and rapidly evolving field. Studies of conditional Dicer knockout mice revealed critical roles for miRNAs in orchestrating kidney development and maintaining the structural and functional integrity of the renal collecting system and glomerular barrier. Expression profiling has provided a reasonably clear picture of miRNAs present in normal kidney and pointed to individual miRNAs that may serve special functional roles therein. Specific miRNAs have been implicated in pathways linked to cystic kidney disease (miR-15a), and Wilms' tumor (miR-17-92). Several miRNAs are upregulated by transforming growth factor beta-1 in models of diabetic nephropathy. Some promote matrix deposition (miR-192 and miR-377) or epithelial-to-mesenchymal transition (miR-200 and miR-205), whereas preliminary findings suggest others might serve protective roles (miR-21). miRNAs recently identified in urinary exosomes could potentially serve as disease biomarkers. Nephrology is in the midst of a miRNA 'revolution' that promises incredible advances in our understanding of genetic regulatory pathways underlying kidney disease, and, with it, new avenues for treatment.
14 January 2009 in Nephrology Dialysis Transplantation
Background. For several decades, it has been thought that the glomerular basement membrane (GBM) provides a charge-selective barrier for glomerular filtration. However, recent evidence has presented challenges to this concept: selective removal of heparan sulfate (HS) moieties that impart a negative charge to the GBM causes little if any increase in proteinuria. Removal of agrin, the major GBM HS-proteoglycan (HSPG), from the GBM causes a profound reduction in the glomerular anionic charge without changing the excretion of a negatively charged tracer. Perlecan is another HSPG present in the GBM, as well as in the mesangium and Bowman's capsule, that could potentially contribute to a charge barrier in the absence of agrin. Methods. Here we studied the nature of the glomerular filtration barrier to albumin in mice lacking the HS chains of perlecan either alone or in combination with podocyte-specific loss of agrin. Results. The results show significant reductions in anionic sites within the GBM in perlecan-HS and in perlecan-HS/agrin double mutants. Podocyte and overall glomerular architecture were normal, and renal function was normal up to 15 months of age with no measurable proteinuria. Moreover, excretion of a negatively charged Ficoll tracer was unchanged as compared to control mice. Conclusions. These findings cast further doubt upon a critical role for the GBM in charge selectivity.